Clinical Trials · NCT03298087
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- VA Office of Research and Development
- Enrollment
- 28
- Start date
- Jul 2018
- Locations
- 3 sites, United States
- Primary endpoint
- Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation)